DPP4 and chronic kidney disease: DPP-4 was previously reported as one of the factors that promotes tissue fibrosis [28]; we have shown that all investigated DPP-4 inhibitors (linagliptin, sitagliptin and alogliptin) decrease plasma concentrations of the fibrosis marker, osteopontin (Table 5), which has recently been called “the killer of patients with CKD” [29], due to its role in vascular calcification.